Every 424B that SPRBD (SPRBD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SPRBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRBD filings page.
Spruce Biosciences is offering 1,150,000 shares of common stock and pre-funded warrants to purchase 50,000 shares. The offering prices are $50.00 per share and $49.99 per pre-funded warrant, with expected gross proceeds of $59,999,500 before underwriting discounts. Net proceeds are estimated at approximately $55.9 million, intended to fund pre-commercial and launch activities, planned clinical trials, working capital, capital expenditures and general corporate purposes.
The pre-funded warrants have a $0.01 exercise price, do not expire, are not expected to be listed, and include beneficial-ownership exercise limits (4.99% default, electable to 9.99%). The underwriters have a 30-day option to purchase up to 180,000 additional shares.
Spruce Biosciences, Inc. is offering shares of its common stock and pre-funded warrants to purchase common stock in a registered primary offering under its shelf registration. The pre-funded warrants have a $0.01 exercise price and do not expire; they are offered in lieu of common stock to certain investors. The prospectus discloses liquidity limits for the pre-funded warrants (no exchange listing expected), an ownership exercise limitation (4.99% default, electable up to 9.99%), and that net proceeds will be used for pre-commercial and launch activities, planned clinical trials, working capital and general corporate purposes. The document also states key capitalization figures as of December 31, 2025 and references an ATM Program with capacity up to $75.0 million.
Spruce Biosciences is offering up to $75.0 million of common stock under an at-the-market sales agreement with Jefferies LLC. The sales may occur from time to time on the Nasdaq Capital Market and other trading venues, with Jefferies acting as agent and receiving a 3.0% commission on gross proceeds.
The prospectus supplement states proceeds may be used to fund clinical programs and for general corporate purposes, including working capital, operating expenses and capital expenditures. The assumed illustrative offering price referenced is $55.87 per share (last reported sale price on March 6, 2026), and the filing notes potential dilution and variability in the number and timing of shares sold.